Abbott Directed to Provide Prescribing Details for Triamcinolone Hexacetonide Pre-Filled Syringe
The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has instructed Abbott Healthcare Pvt. to submit proposed prescribing information and supporting data for Triamcinolone Hexacetonide Injectable Suspension USP 40 mg/2 ml (Pre-filled syringe).
The directive followed a detailed review of the company's proposal during the SEC meeting on September 17, 2025, at CDSCO headquarters in New Delhi.
Abbott presented its proposal for introducing Triamcinolone Hexacetonide Injectable Suspension USP 40 mg/2 ml Pre-filled Syringe for use in already approved indications, along with a detailed justification of the rationale and clinical need for this new presentation.
Abbott must provide prescribing information and data for the new pre-filled syringe.
Author summary: Abbott directed to submit data for Triamcinolone Hexacetonide.
More News
- Elon Musk could step down if Tesla pay plan is rejected
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- The environmental impact of the 2026 World Cup
- The new age of pediatric medication awareness - Express Healthcare
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Staffordshire Leader Reacts to "Squandered" Billions of Taxpayers' Money on Asylum Hotels - Staffordshire County Council Newsroom
- Want to build infra for eyewear like Jio's optical fibre: Lenskart CEO - Industry News | The Financial Express
- Biopic reintroduces female revolutionary hero - BusinessWorld Online